ES2584055T3 - Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa - Google Patents

Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa Download PDF

Info

Publication number
ES2584055T3
ES2584055T3 ES11729889.3T ES11729889T ES2584055T3 ES 2584055 T3 ES2584055 T3 ES 2584055T3 ES 11729889 T ES11729889 T ES 11729889T ES 2584055 T3 ES2584055 T3 ES 2584055T3
Authority
ES
Spain
Prior art keywords
compound
compound according
spiro
ethanone
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11729889.3T
Other languages
English (en)
Spanish (es)
Inventor
Simon Feldbaek Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of ES2584055T3 publication Critical patent/ES2584055T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
ES11729889.3T 2010-06-24 2011-06-24 Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa Active ES2584055T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US358209P 2002-02-19
US35820910P 2010-06-24 2010-06-24
PCT/DK2011/000069 WO2011160632A1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
ES2584055T3 true ES2584055T3 (es) 2016-09-23

Family

ID=44351701

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11729889.3T Active ES2584055T3 (es) 2010-06-24 2011-06-24 Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa
ES16020112T Active ES2733092T3 (es) 2010-06-24 2011-06-24 Derivados de benzodioxol como inhibidores de la fosfodiesterasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16020112T Active ES2733092T3 (es) 2010-06-24 2011-06-24 Derivados de benzodioxol como inhibidores de la fosfodiesterasa

Country Status (29)

Country Link
US (3) US8980905B2 (enExample)
EP (2) EP3070091B1 (enExample)
JP (2) JP6174997B2 (enExample)
KR (1) KR101864578B1 (enExample)
CN (1) CN102958937B (enExample)
AU (1) AU2011269429B2 (enExample)
BR (1) BR112012032813B1 (enExample)
CA (1) CA2802895C (enExample)
CY (2) CY1117862T1 (enExample)
DK (2) DK3070091T3 (enExample)
ES (2) ES2584055T3 (enExample)
HR (2) HRP20160919T1 (enExample)
HU (2) HUE030081T2 (enExample)
IL (1) IL223329A (enExample)
LT (2) LT3070091T (enExample)
MX (1) MX2012014131A (enExample)
MY (1) MY157481A (enExample)
NZ (1) NZ603895A (enExample)
PL (2) PL3070091T3 (enExample)
PT (2) PT3070091T (enExample)
RS (2) RS55104B1 (enExample)
RU (1) RU2583787C2 (enExample)
SG (1) SG186140A1 (enExample)
SI (2) SI2585469T1 (enExample)
TR (1) TR201909709T4 (enExample)
TW (1) TWI507410B (enExample)
UA (1) UA109140C2 (enExample)
WO (1) WO2011160632A1 (enExample)
ZA (1) ZA201209031B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822392B (zh) * 2012-11-30 2017-09-08 利奥制药有限公司 抑制活化的t‑细胞中il‑22表达的方法
CA2953284A1 (en) 2014-06-23 2015-12-30 Leo Pharma A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP3390407B1 (en) * 2015-12-18 2023-10-11 UNION therapeutics A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3642210B1 (en) 2017-06-20 2024-11-13 UNION therapeutics A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
SI3911304T1 (sl) * 2019-01-15 2023-12-29 UNION therapeutics A/S Formulacije tablet s prirejenim sproščanjem, ki vsebujejo inhibitorje fosfodiesteraze
AU2020316072A1 (en) * 2019-07-24 2022-02-24 Constellation Pharmaceuticals, Inc. EZH2 inhibition in combination therapies for the treatment of cancers
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
AU2022245186A1 (en) 2021-03-22 2023-10-05 UNION therapeutics A/S Treatment of hidradenitis suppurativa with orismilast
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220041B (hu) 1993-07-02 2001-10-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
CN1163493C (zh) 1995-05-19 2004-08-25 协和发酵工业株式会社 含氧杂环化合物
CZ371998A3 (cs) * 1996-05-20 1999-03-17 Darwin Discovery Limited Benzofuranové karboxamidy a jejich terapeutické použití
WO1998022455A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP5122974B2 (ja) * 2004-12-17 2013-01-16 グレンマーク・ファーマシューティカルズ・エスエー 炎症性障害およびアレルギー障害の治療に有用な新規な複素環式化合物
ZA200905371B (en) * 2007-02-28 2010-10-27 Leo Pharma As Novel phosphodiesterase Inhibitors
RS53407B (sr) * 2007-02-28 2014-10-31 Leo Pharma A/S Novi inhibitori fosfodiesteraze
EP2794603B1 (en) * 2011-12-21 2016-06-15 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors

Also Published As

Publication number Publication date
MY157481A (en) 2016-06-15
US8980905B2 (en) 2015-03-17
CN102958937B (zh) 2016-03-30
US20160022657A1 (en) 2016-01-28
TR201909709T4 (tr) 2019-07-22
KR101864578B1 (ko) 2018-06-07
AU2011269429B2 (en) 2015-07-09
PL3070091T3 (pl) 2019-09-30
RS58945B1 (sr) 2019-08-30
JP2016164168A (ja) 2016-09-08
HUE030081T2 (en) 2017-04-28
EP3070091B1 (en) 2019-04-17
BR112012032813A2 (pt) 2016-11-08
US20130123291A1 (en) 2013-05-16
PT3070091T (pt) 2019-07-22
AU2011269429A1 (en) 2012-12-20
DK3070091T3 (da) 2019-07-08
US9637499B2 (en) 2017-05-02
CA2802895A1 (en) 2011-12-29
CY1117862T1 (el) 2017-05-17
CN102958937A (zh) 2013-03-06
JP2013529602A (ja) 2013-07-22
RU2013103079A (ru) 2014-07-27
BR112012032813B1 (pt) 2022-02-01
LT2585469T (lt) 2016-10-10
MX2012014131A (es) 2013-01-29
SI3070091T1 (sl) 2019-08-30
RS55104B1 (sr) 2016-12-30
NZ603895A (en) 2014-10-31
KR20130038341A (ko) 2013-04-17
LT3070091T (lt) 2019-07-25
JP6174997B2 (ja) 2017-08-02
UA109140C2 (uk) 2015-07-27
RU2583787C2 (ru) 2016-05-10
HK1182699A1 (zh) 2013-12-06
EP2585469B1 (en) 2016-05-25
IL223329A (en) 2017-01-31
WO2011160632A1 (en) 2011-12-29
HRP20191136T1 (hr) 2019-09-20
TWI507410B (zh) 2015-11-11
TW201206940A (en) 2012-02-16
CA2802895C (en) 2019-05-21
HUE044301T2 (hu) 2019-10-28
IL223329A0 (en) 2013-02-03
US9273064B2 (en) 2016-03-01
ZA201209031B (en) 2014-02-26
EP2585469A1 (en) 2013-05-01
EP3070091A1 (en) 2016-09-21
DK2585469T3 (en) 2016-08-29
ES2733092T3 (es) 2019-11-27
PL2585469T3 (pl) 2017-07-31
HRP20160919T1 (hr) 2016-10-07
SG186140A1 (en) 2013-01-30
US20150111915A1 (en) 2015-04-23
PT2585469T (pt) 2016-08-29
SI2585469T1 (sl) 2016-11-30
CY1122201T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
ES2584055T3 (es) Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa
ES2478670T3 (es) Nuevos inhibidores de la fosfodiesterasa
EP3578561A1 (en) Spiro compounds
ES2981006T3 (es) Pirazoloazepin-4-onas sustituidas y su uso como inhibidores de la fosfodiesterasa
TWI432439B (zh) 新穎磷酸二酯酶抑制劑
TW202540096A (zh) 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途
HK1182699B (en) Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors